Zobrazeno 1 - 10 of 80 pro vyhledávání: '"H. J. de Voogt"'
1
Preliminary Evaluation of Alpha-adrenergic Blocking Agents in Children with Neurogenic Bladder due to Myelomeningocele
Autor: H. J. De Voogt, C. Van Der Sluis
Publikováno v: Developmental Medicine & Child Neurology. 18:82-88
SUMMARY Twenty children with myelomeningocele and neurogenic bladder dysfunction were treated with alpha-adrenergic blocking agents. The results were satisfactory and are considered to justify the use of these drugs, especially for children who have
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da1232c3cbcfa0db91aedeceee50e1ee
https://doi.org/10.1111/j.1469-8749.1976.tb04285.x
Zobrazit plný text záznamu
2
The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials
Autor: Richard Sylvester, L. Denis, H. J. De Voogt
Publikováno v: European urology
Introduction and Objectives: The EORTC conducted two randomized phase III trials of maximal androgen blockade (MAB) in 695 patients with metastatic prostate cancer. Trial 30843 compared orchidectomy or buserelin to buserelin plus cyproterone acetate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::632c27ec3cfcb49c966f2ef362f20eda
https://doi.org/10.1159/000019545
Zobrazit plný text záznamu
3
Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer
Autor: Jan G. M. Klijn, Urs E. Studer, H. J. de Voogt, Richard Sylvester, M. De Pauw, Fritz H. Schröder
Publikováno v: Cancer. 72:3858-3862
In an open, multicenter, three-armed, randomized study, we compared the effects of short-term (2 weeks) and continuous addition of the antiandrogen cyproterone acetate to the luteinizing hormone-releasing hormone agonist buserelin to those of orchide
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c7d7cc0c71cc0ab07d8cd5a9a8e8c05
https://doi.org/10.1002/1097-0142(19931215)72:12+<3858::aid-cncr2820721719>3.0.co
Zobrazit plný text záznamu
6
Orchidectomy versus buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843
Autor: M. De Pauw, U. Studer, H. J. de Voogt, Jan G. M. Klijn, Fritz H. Schröder, Richard Sylvester
Publikováno v: The Journal of Steroid Biochemistry and Molecular Biology. 37:965-969
This prospective randomized phase III trial compares orchidectomy as standard androgen-deprivative therapy of advanced (metastatic) prostatic cancer with treatment using the LHRH agonist Buserelin® administered as nasal spray 3 daily doses of 400 μ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272e94ba6e3509748d7fbc1d8d837bad
https://doi.org/10.1016/0960-0760(90)90451-p
Zobrazit plný text záznamu
7
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer
Autor: H. J. de Voogt, M. De Pauw, Richard Sylvester, Jan G. M. Klijn, Fritz H. Schröder, Urs E. Studer
Publikováno v: European Urology, 33, 152-158. Elsevier
This is the final analysis of EORTC GU Group Trial 30843 in which the treatment of advanced, metastatic prostate cancer with a combination of the LHRH agonist buserelin (nasal spray) and cyproterone acetate (Androcur), either continuously of only dur
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5921dfb141de710b78db0a4d7a0bf708
https://pure.eur.nl/en/publications/14fc19cf-09ef-4cb3-84f3-9ccc694a0650
Zobrazit plný text záznamu
8
Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group
Autor: J G, Klijn, H J, de Voogt, U E, Studer, F H, Schröder, R, Sylvester, M, De Pauw
Publikováno v: Cancer. 72
In an open, multicenter, three-armed, randomized study, we compared the effects of short-term (2 weeks) and continuous addition of the antiandrogen cyproterone acetate to the luteinizing hormone-releasing hormone agonist buserelin to those of orchide
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2f4f1dfb83b0ec7c4fcc7eccf4fa3217
https://pubmed.ncbi.nlm.nih.gov/8252504
Zobrazit plný text záznamu
10
The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents
Autor: H J, de Voogt, H, Adenauer, W G, Widdra
Publikováno v: Scandinavian journal of urology and nephrology. Supplementum. 138
In the ten years from 1979-1988, a total of 1725 patients with advanced prostatic cancer were entered into 28 studies, in which Buserelin as a nasal spray was the main androgen deprivation therapy. Patients treated with orchiectomy or other anti-andr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fab487872112d047e79338994be536e2
https://pubmed.ncbi.nlm.nih.gov/1838426
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje